Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeNO has obtained a sixth patent for its inhaled Nitrosyl nitric oxide (NO) product, currently evaluating in two Phase 2 trials.
Subscribe to our email newsletter
The newly-issued patent relates to the GeNO cartridge technology that eliminates nitrogen dioxide (NO2) from the gas being delivered to the patient.
Out of two Phase 2 trials, one trial is using the product as a diagnostic in pulmonary arterial hypertension (PAH) to obtain preliminary safety and feasibility data from short term (15 minute) administration of inhaled nitric oxide.
However, the second trial relates to dose-escalation for the treatment of pulmonary hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF).